Citations

Mayo Clinic

Showing 10 of 108599 citations.

Allegations of Failure to Obtain Informed Consent in Spinal Surgery Medical Malpractice Claims
Grauberger, Jennifer , Kerezoudis, Panagiotis , Choudhry, Asad , Alvi, Mohammed Ali , Currier, Bradford L. , Bydon, Mohamad , Choudhry, Asad J, Currier, Bradford, Nassr, Ahmad , Alvi, Mohammed Ali

JAMA Surgery | April 26, 2017 | Volume: 152 | Issue: 6 | Pages: e170544

10.1001/jamasurg.2017.0544 | PMID 28445561 Get It

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
Adiwijaya, B., Kim, J., Láng, István, Csőszi, Tibor , Cubillo, Antonio , Chen, J‐S, Park, J. O. , Kim, J-S, Rau, K-M., Melichar, Bohuslav , Gallego, JB, Fitzgerald, Jonathan B., Belanger, Bruce , Molnár, István, Ma, WW, Chen, J‐S, Wong, Ma‐Li

Clinical Pharmacology & Therapeutics | April 26, 2017 | Volume: 102 | Issue: 6 | Pages: 997-1005

10.1002/cpt.720 | PMID 28445610 Get It

Nanoliposomal irinotecan (nal‐IRI) is a liposomal formulation of irinotecan with a longer half‐life (t1/2), higher plasma total irinotecan (tIRI), and lower SN‐38 maximum concentration (Cmax) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal‐IRI was performed for tIRI and total SN‐38 (tSN38) using patient samples from six studies. PK‐safety association was evaluated for neutropenia and diarrhea in 353 patients. PK‐efficacy association was evaluated from a phase III study in pancreatic cancer NAPOLI1. Efficacy was associated with longer duration of unencapsulated SN‐38 (uSN38) above a threshold and higher Cavgof tIRI, tSN38, and uSN38. Neutropenia was associated with uSN38Cmaxand diarrhea with tIRICmax. Baseline predictive factors were race, body surface area, and bilirubin. Analysis identified PK factors associated with efficacy, safety, and predictive baseline factors. The results support the benefit of nal‐IRI dose of 70 mg/m2(free‐base; equivalent to 80 mg/m2salt base) Q2W over 100 mg/m2Q3W.
Nicotine Replacement Therapy
Flowers, L

American Journal of Psychiatry Residents' Journal | April 26, 2017 | Volume: 11 | Issue: 6 | Pages: 4-7

10.1176/appi.ajp-rj.2016.110602 Get It

In Reply to Willett
Bonnes, Sara L. , Beckman, Thomas J. , Wittich, Christopher M. , Bonnes, Sara

Academic Medicine | April 26, 2017 | Volume: 92 | Issue: 5 | Pages: 573-574

10.1097/acm.0000000000001655 | PMID 28441193 Get It

The Weaponization of Medical Professionalism
Lee, James H.

Academic Medicine | April 26, 2017 | Volume: 92 | Issue: 5 | Pages: 579-580

10.1097/acm.0000000000001647 | PMID 28441205 Get It

Subarachnoid and intraperitoneal hemorrhage secondary to segmental arterial mediolysis: A case report and review of the literature
Welch, Brian T. , Brinjikji, Waleed , Stockland, Andrew H., Lanzino, Giuseppe

Interventional Neuroradiology | April 26, 2017 | Volume: 23 | Issue: 4 | Pages: 378-381

10.1177/1591019917703074 | PMID 28443482 Get It

Background Segmental arterial mediolysis (SAM) is an uncommon or underdiagnosed arteriopathy that presents with life-threatening hemorrhage. SAM can affect the intracranial, spinal, and visceral arteries, with reported cases of concomitant intracranial and visceral hemorrhage. Case description We present the case of a 61-year-old male with concurrent subarachnoid and intraperitoneal hemorrhage caused by simultaneously bleeding posterior spinal artery and splenic artery pseudoaneurysms. The posterior spinal artery pseudoaneurysms were treated with selective injection of polyvinyl alcohol particles into the posterior spinal artery, while the splenic artery pseudoaneurysm was treated with Gelfoam embolization. The constellation of imaging, clinical, and laboratory features led to a presumptive diagnosis of SAM, which remains the only reported cause of concurrent neurovascular and visceral artery aneurysm rupture. Conclusion SAM is a key diagnostic consideration in cases of concomitant intracranial, spinal, and visceral artery aneurysm rupture.
Partial Resolution of Tardive Dyskinesia with Treatment of Co-existing Thyrotoxicosis *
Leder, Robert, Kirch, Darrell G., Clay, Keith L., Freedman, Robert I., Murphy, Robert C.

The Canadian Journal of Psychiatry | April 26, 2017 | Volume: 28 | Issue: 2 | Pages: 134-136

10.1177/070674378302800212 | PMID 6839282 Get It

Neuroleptic-induced tardive dyskinesia improved after treatment of thyrotoxicosis. Neuroleptic blood levels indicated that the improvement was not caused by masking of the symptoms by rising drug levels. Dopamine metabolite measurements suggested that the thyrotoxicosis caused an increase in the sensitivity of caudate neurons to dopamine, rather than a change in release of dopamine.
Endothelin-A Receptor Antagonism Retards the Progression of Murine Sickle Cell Nephropathy
Nath, Karl A. , Katušić, Zvonimir S.

Journal of the American Society of Nephrology | April 25, 2017 | Volume: 28 | Issue: 8 | Pages: 2253-2255

10.1681/asn.2017030320 | PMID 28442492 Get It

Combined AURKA and H3K9 Methyltransferase Targeting Inhibits Cell Growth By Inducing Mitotic Catastrophe
Mathison, Angela , Salmonson, Ann, Missfeldt, Mckenna, Bintz, Jennifer , Williams, Monique , Kossak, Sarah, Nair, Asha, Assuncao, Thiago M. de , Christensen, Trace , Buttar, Navtej , Lomberk, Gwen , De Assuncao, Thiago M, Huebert, Robert, Iovanna, Juan , Huebert, Robert C. , Lomberk, Gwen L , Mathison, Angela J

Molecular Cancer Research | April 25, 2017 | Volume: 15 | Issue: 8 | Pages: 984-997

10.1158/1541-7786.mcr-17-0063 | PMID 28442587 Get It

Abstract The current integrative pathobiologic hypothesis states that pancreatic cancer (PDAC) develops and progresses in response to an interaction between known oncogenes and downstream epigenomic regulators. Congruently, this study tests a new combinatorial therapy based on the inhibition of the Aurora kinase A (AURKA) oncogene and one of its targets, the H3K9 methylation–based epigenetic pathway. This therapeutic combination is effective at inhibiting the in vitro growth of PDAC cells both, in monolayer culture systems, and in three-dimensional spheroids and organoids. The combination also reduces the growth of PDAC xenografts in vivo. Mechanistically, it was found that inhibiting methyltransferases of the H3K9 pathway in cells, which are arrested in G2–M after targeting AURKA, decreases H3K9 methylation at centromeres, induces mitotic aberrations, triggers an aberrant mitotic check point response, and ultimately leads to mitotic catastrophe. Combined, these data describe for the first time a hypothesis-driven design of an efficient combinatorial treatment that targets a dual oncogenic–epigenomic pathway to inhibit PDAC cell growth via a cytotoxic mechanism that involves perturbation of normal mitotic progression to end in mitotic catastrophe. Therefore, this new knowledge has significant mechanistic value as it relates to the development of new therapies as well as biomedical relevance. Implications: These results outline a model for the combined inhibition of a genetic-to-epigenetic pathway to inhibit cell growth and suggest an important and provocative consideration for harnessing the capacity of cell-cycle inhibitors to enhance the future use of epigenetic inhibitors. Mol Cancer Res; 15(8); 984–97. ©2017 AACR.
The Utility of Routine Postoperative Radiographs After Pinning of Pediatric Supracondylar Humerus Fractures
Karalius, Vytas P. , Stanfield, Jacob, Ashley, Philip, Lewallen, Laura, deDeugd, Casey, Walker, Janet L. , Larson, A. Noelle , Milbrandt, Todd A. , Larson, A Noelle

Journal of Pediatric Orthopaedics | April 25, 2017 | Volume: 37 | Issue: 5 | Pages: e309-e312

10.1097/bpo.0000000000001000 | PMID 28441278 Get It

Background: The purpose of this study was to determine the frequency with which postoperative radiographs resulted in a change in management following closed reduction and percutaneous pinning of displaced pediatric supracondylar humerus fractures. We hypothesize that only the initial postoperative radiograph will lead to changes in management of operative supracondylar humerus fractures. Methods: A retrospective review was performed at 2 level I pediatric trauma centers. Inclusion criteria were patients below 18 years of age who sustained supracondylar humerus fractures (Gartland type II, III, IV) who were operatively treated from 2008 to 2013 with adequate radiographic follow-up. Patients with flexion type, intra-articular, transphyseal, and open fractures were excluded from the study. Routine radiographs were taken at initial follow-up (1 wk postoperatively) and at pin removal (3 to 4 wk postoperatively). Results: The final analysis included 572 patients. Initial postoperative radiographs changed treatment in 9 patients (1.6%), including revision surgeries, 2 pin adjustments, and 2 early pin removals. At the time of pin removal, 20 (3.5%) patients required further immobilization. There were no changes to the initial plan for continued nonoperative treatment at final follow-up (6 to 8 wk postoperatively). Conclusions: In this large retrospective series of patients treated with closed reduction and percutaneous pinning of displaced supracondylar humerus fractures, radiographs at 3 weeks do not reveal a need to return to the operating room or other significant pathology. These findings suggest that radiographs should be obtained within 7 to 10 days postoperatively for type III fractures and may only need to be repeated if the clinical situation warrants it, such as severe fracture pattern, persistent pain, or clinical deformity. Level of Evidence: Level IV—case series.